135 related articles for article (PubMed ID: 12624523)
21. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
Marsillach J; MartÃnez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
[TBL] [Abstract][Full Text] [Related]
22. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?
Prutchi-Sagiv S; Golishevsky N; Oster HS; Katz O; Cohen A; Naparstek E; Neumann D; Mittelman M
Br J Haematol; 2006 Dec; 135(5):660-72. PubMed ID: 17107348
[TBL] [Abstract][Full Text] [Related]
23. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients.
Kwan JT; Pratt RD;
Curr Med Res Opin; 2007 Feb; 23(2):307-11. PubMed ID: 17288685
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma.
Katodritou E; Speletas M; Zervas K; Kapetanos D; Georgiou E; Christoforidou A; Pavlitou A; Sion M; Christakis J
Lab Hematol; 2006; 12(1):47-54. PubMed ID: 16513546
[TBL] [Abstract][Full Text] [Related]
25. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease.
Spinowitz BS; Pratt RD;
Curr Med Res Opin; 2006 Dec; 22(12):2507-13. PubMed ID: 17166333
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
27. Erythropoietin (r-HuEPO) in the treatment of anemia of nodular sclerosis type Hodgkin's disease--a preliminary report.
Wojtukiewicz MZ; Sawicki Z; Radziwon P
Rocz Akad Med Bialymst; 2000; 45():145-9. PubMed ID: 11712426
[TBL] [Abstract][Full Text] [Related]
28. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
Galli M; Elice F; Crippa C; Comotti B; Rodeghiero F; Barbui T
Haematologica; 2004 Sep; 89(9):1141-2. PubMed ID: 15377478
[TBL] [Abstract][Full Text] [Related]
29. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
30. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.
Heras P; Kritikos K; Hatzopoulos A; Mitsibounas D
Eur J Cancer Care (Engl); 2008 Nov; 17(6):619-23. PubMed ID: 18707619
[TBL] [Abstract][Full Text] [Related]
31. Selective use of recombinant human erythropoietin in pregnant patients with severe anemia or nonresponsive to iron sucrose alone.
Krafft A; Bencaiova G; Breymann C
Fetal Diagn Ther; 2009; 25(2):239-45. PubMed ID: 19506383
[TBL] [Abstract][Full Text] [Related]
32. Recombinant human erythropoietin: has treatment reached its full potential?
Fishbane S
Semin Dial; 2006; 19(1):1-4. PubMed ID: 16423172
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia.
Tzekova V; Mihaylov G; Elezovic I; Koytchev R;
Curr Med Res Opin; 2009 Jul; 25(7):1689-97. PubMed ID: 19505200
[TBL] [Abstract][Full Text] [Related]
34. Role of erythropoietin in anemia after heart transplantation.
Gleissner CA; Klingenberg R; Staritz P; Koch A; Ehlermann P; Wiggenhauser A; Dengler TJ
Int J Cardiol; 2006 Oct; 112(3):341-7. PubMed ID: 16309765
[TBL] [Abstract][Full Text] [Related]
35. [Human recombinant erythropoietin in the treatment of the severe anemia following labor (a preliminary report)].
Malinova M
Akush Ginekol (Sofiia); 1999; 38(4):13-5. PubMed ID: 10726343
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
37. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
38. Treatment of chronic skin ulcers in individuals with anemia of chronic disease using recombinant human erythropoietin (EPO): a review of four cases.
Keast DH; Fraser C
Ostomy Wound Manage; 2004 Oct; 50(10):64-70. PubMed ID: 15509883
[TBL] [Abstract][Full Text] [Related]
39. [Guidelines for the treatment of anemia in chronic renal failure].
Triolo G;
G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
[TBL] [Abstract][Full Text] [Related]
40. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study.
de Francisco AL; Sulowicz W; Klinger M; Niemczyk S; Vargemezis V; Metivier F; Dougherty FC; Oguey D;
Int J Clin Pract; 2006 Dec; 60(12):1687-96. PubMed ID: 17109676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
